{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 14,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 2
      },
      "2": {
        "core": 1,
        "branch": 4
      },
      "3": {
        "core": 1,
        "branch": 1
      },
      "4": {
        "core": 1,
        "branch": 3
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A1 → G)",
        "prover9_expression": "(approved(clinical_trial, drug_x) -> approved_for_market(drug_x))",
        "natural": "If drug X is approved for clinical trial, then drug X is approved for market."
      },
      {
        "id": "Rule2",
        "formal": "(A10 → (A7 → (A6 → G)))",
        "prover9_expression": "(completes_phase_iii(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Provided that drug Y completes phase III, if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
      },
      {
        "id": "Rule3",
        "formal": "(A12 → (¬(A9 → A8) → A11))",
        "prover9_expression": "(files_patent(company_a, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
        "natural": "In case company A files a patent for drug X, then if it is not the case that drug X completing phase III leads to drug X receiving FDA approval, an appeal of the FDA decision is initiated."
      },
      {
        "id": "Rule4",
        "formal": "(A12 ∨ A13)",
        "prover9_expression": "(files_patent(company_a, drug_x) | files_patent(company_b, drug_x))",
        "natural": "Either company A files a patent for drug X, or company B files a patent for drug X."
      },
      {
        "id": "Rule5",
        "formal": "(A13 → (¬(A9 → A8) → A11))",
        "prover9_expression": "(files_patent(company_b, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
        "natural": "Assuming company B files a patent for drug X, then if it is not the case that drug X completing phase III implies drug X receives FDA approval, an appeal of the FDA decision is initiated."
      },
      {
        "id": "Rule6",
        "formal": "(A17 → A18)",
        "prover9_expression": "(receives_priority_status(drug_x) -> delayed_approval(drug_x))",
        "natural": "Whenever drug X receives priority status, approval of drug X is delayed."
      },
      {
        "id": "Rule7",
        "formal": "(A19 ∨ A20)",
        "prover9_expression": "(submits_additional_data(company_a) | submits_additional_data(company_b))",
        "natural": "Company A submits additional data or company B submits additional data."
      },
      {
        "id": "Rule8",
        "formal": "(A2 → G)",
        "prover9_expression": "(approved(clinical_trial, drug_y) -> approved_for_market(drug_x))",
        "natural": "Provided that drug Y is approved for clinical trial, drug X is approved for market."
      },
      {
        "id": "Rule9",
        "formal": "(A20 → ¬A18)",
        "prover9_expression": "(submits_additional_data(company_b) -> -delayed_approval(drug_x))",
        "natural": "In case company B submits additional data, then approval of drug X is not delayed."
      },
      {
        "id": "Rule10",
        "formal": "(A21 ∨ (A19 → ¬A18))",
        "prover9_expression": "(requests_extension(review_period) | (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
        "natural": "Either an extension of the review period is requested, or if company A submits additional data, then approval of drug X is not delayed."
      },
      {
        "id": "Rule11",
        "formal": "(A22 → A1)",
        "prover9_expression": "(positive_results(clinical_trial, drug_x) -> approved(clinical_trial, drug_x))",
        "natural": "If the clinical trial yields positive results for drug X, then drug X is approved for clinical trial."
      },
      {
        "id": "Rule12",
        "formal": "(A22 ∨ A23)",
        "prover9_expression": "(positive_results(clinical_trial, drug_x) | positive_results(clinical_trial, drug_y))",
        "natural": "The clinical trial yields positive results for drug X or the clinical trial yields positive results for drug Y."
      },
      {
        "id": "Rule13",
        "formal": "(A24 → (A23 → A2))",
        "prover9_expression": "(has_collaboration(research_lab, company_a) -> (positive_results(clinical_trial, drug_y) -> approved(clinical_trial, drug_y)))",
        "natural": "Assuming the research lab has collaboration with company A, then if the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial."
      },
      {
        "id": "Rule14",
        "formal": "(A26 → (A25 ∨ A3))",
        "prover9_expression": "(has_partnership(company_a, research_lab) -> (secures_investment(company_a) | has_funding(research_lab, project_alpha)))",
        "natural": "In case company A has a partnership with the research lab, then either company A secures investment or the research lab has funding for project alpha."
      },
      {
        "id": "Rule15",
        "formal": "(A29 ∨ A30)",
        "prover9_expression": "(meets_manufacturing_standards(drug_x) | meets_manufacturing_standards(drug_y))",
        "natural": "Drug X meets manufacturing standards or drug Y meets manufacturing standards."
      },
      {
        "id": "Rule16",
        "formal": "(A3 → (A1 ∨ A2))",
        "prover9_expression": "(has_funding(research_lab, project_alpha) -> (approved(clinical_trial, drug_x) | approved(clinical_trial, drug_y)))",
        "natural": "Provided that the research lab has funding for project alpha, then either drug X is approved for clinical trial or drug Y is approved for clinical trial."
      },
      {
        "id": "Rule17",
        "formal": "(A30 → (A6 → G))",
        "prover9_expression": "(meets_manufacturing_standards(drug_y) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
        "natural": "Assuming drug Y meets manufacturing standards, then if drug X passes the safety test, drug X is approved for market."
      },
      {
        "id": "Rule18",
        "formal": "(A32 → A8)",
        "prover9_expression": "(completes_stability_study(drug_x) -> receives_fda_approval(drug_x))",
        "natural": "If drug X completes the stability study, then drug X receives FDA approval."
      },
      {
        "id": "Rule19",
        "formal": "(A32 ∨ A33)",
        "prover9_expression": "(completes_stability_study(drug_x) | completes_stability_study(drug_y))",
        "natural": "Either drug X completes the stability study, or drug Y completes the stability study."
      },
      {
        "id": "Rule20",
        "formal": "(A33 → A34)",
        "prover9_expression": "(completes_stability_study(drug_y) -> passes_quality_control(drug_x))",
        "natural": "In case drug Y completes the stability study, then drug X passes quality control."
      },
      {
        "id": "Rule21",
        "formal": "(A34 → A35)",
        "prover9_expression": "(passes_quality_control(drug_x) -> passes_quality_control(drug_y))",
        "natural": "Whenever drug X passes quality control, drug Y passes quality control."
      },
      {
        "id": "Rule22",
        "formal": "(A35 → (A7 → (A6 → G)))",
        "prover9_expression": "(passes_quality_control(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Provided that drug Y passes quality control, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market."
      },
      {
        "id": "Rule23",
        "formal": "(A36 → A8)",
        "prover9_expression": "(completes_bioequivalence_study(drug_x) -> receives_fda_approval(drug_x))",
        "natural": "If drug X completes the bioequivalence study, then drug X receives FDA approval."
      },
      {
        "id": "Rule24",
        "formal": "(A36 ∨ A37)",
        "prover9_expression": "(completes_bioequivalence_study(drug_x) | completes_bioequivalence_study(drug_y))",
        "natural": "Either drug X completes the bioequivalence study, or drug Y completes the bioequivalence study."
      },
      {
        "id": "Rule25",
        "formal": "(A39 ∨ (¬(A37 → (A7 → (A6 → G))) → A38))",
        "prover9_expression": "(accepts_regulatory_submission(agency) | (-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> initiates_reformulation(drug_x)))",
        "natural": "Either the agency accepts the regulatory submission, or if it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then reformulation of drug X is initiated."
      },
      {
        "id": "Rule26",
        "formal": "(A40 → A41)",
        "prover9_expression": "(has_gmp_certification(facility_a) -> has_gmp_certification(facility_b))",
        "natural": "If facility A has GMP certification, then facility B has GMP certification."
      },
      {
        "id": "Rule27",
        "formal": "(A41 → (A14 ∨ G))",
        "prover9_expression": "(has_gmp_certification(facility_b) -> (passes_toxicity_test(drug_x) | approved_for_market(drug_x)))",
        "natural": "Provided that facility B has GMP certification, then drug X passes the toxicity test or drug X is approved for market."
      },
      {
        "id": "Rule28",
        "formal": "(A42 → ¬A18)",
        "prover9_expression": "(provides_clinical_data(company_a) -> -delayed_approval(drug_x))",
        "natural": "Whenever company A provides clinical data, then it is not the case that approval of drug X is delayed."
      },
      {
        "id": "Rule29",
        "formal": "(A43 → A42)",
        "prover9_expression": "(submits_dossier(company_a) -> provides_clinical_data(company_a))",
        "natural": "If company A submits a dossier, then company A provides clinical data."
      },
      {
        "id": "Rule30",
        "formal": "(A45 ∨ A46)",
        "prover9_expression": "(submits_dossier(company_b) | provides_additional_analysis(company_b))",
        "natural": "Company B submits a dossier or company B provides additional analysis."
      },
      {
        "id": "Rule31",
        "formal": "(A46 → ¬A18)",
        "prover9_expression": "(provides_additional_analysis(company_b) -> -delayed_approval(drug_x))",
        "natural": "In case company B provides additional analysis, then approval of drug X is not delayed."
      },
      {
        "id": "Rule32",
        "formal": "(A47 ∨ (A45 → A44))",
        "prover9_expression": "(requests_advisory_meeting(company_a) | (submits_dossier(company_b) -> provides_clinical_data(company_b)))",
        "natural": "Either company A requests an advisory meeting, or if company B submits a dossier, then company B provides clinical data."
      },
      {
        "id": "Rule33",
        "formal": "(A48 → (A19 → ¬A18))",
        "prover9_expression": "(responds_to_deficiency_letter(company_a) -> (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
        "natural": "Provided that company A responds to the deficiency letter, then if company A submits additional data, approval of drug X is not delayed."
      },
      {
        "id": "Rule34",
        "formal": "(A9 ∨ A10)",
        "prover9_expression": "(completes_phase_iii(drug_x) | completes_phase_iii(drug_y))",
        "natural": "Drug X completes phase III or drug Y completes phase III."
      },
      {
        "id": "Rule35",
        "formal": "(¬(A14 ∨ G) → A15)",
        "prover9_expression": "(-(passes_toxicity_test(drug_x) | approved_for_market(drug_x)) -> fails_toxicity_test(drug_x))",
        "natural": "If it is not the case that drug X passes the toxicity test or drug X is approved for market, then drug X fails the toxicity test."
      },
      {
        "id": "Rule36",
        "formal": "(¬(A29 → (A6 → G)) → A31)",
        "prover9_expression": "(-(meets_manufacturing_standards(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))) -> fails_manufacturing_audit(drug_x))",
        "natural": "In case it is not the case that drug X meeting manufacturing standards leads to drug X being approved for market under safety, then drug X fails the manufacturing audit."
      },
      {
        "id": "Rule37",
        "formal": "(¬(A37 → (A7 → (A6 → G))) → ¬A38)",
        "prover9_expression": "(-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> -initiates_reformulation(drug_x))",
        "natural": "If it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then it is not the case that reformulation of drug X is initiated."
      },
      {
        "id": "Rule38",
        "formal": "(¬(A49 → A48) → A50)",
        "prover9_expression": "(-(receives_deficiency_letter(company_a) -> responds_to_deficiency_letter(company_a)) -> faces_regulatory_sanctions(company_a))",
        "natural": "Provided that it is not the case that company A receiving a deficiency letter leads to company A responding to the deficiency letter, then company A faces regulatory sanctions."
      },
      {
        "id": "Rule39",
        "formal": "(¬(A9 → A8) → ¬A11)",
        "prover9_expression": "(-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> -initiates_appeal(fda_decision))",
        "natural": "Assuming it is not the case that drug X completing phase III implies drug X receives FDA approval, then it is not the case that an appeal of the FDA decision is initiated."
      },
      {
        "id": "Rule40",
        "formal": "(¬(¬(A6 → G) → A27) → A28)",
        "prover9_expression": "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> waives_retesting_requirement(drug_x))",
        "natural": "Provided that it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then the retesting requirement for drug X is waived."
      },
      {
        "id": "Rule41",
        "formal": "(¬(¬(A6 → G) → A27) → ¬A28)",
        "prover9_expression": "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> -waives_retesting_requirement(drug_x))",
        "natural": "If it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then it is not the case that the retesting requirement for drug X is waived."
      },
      {
        "id": "Rule42",
        "formal": "(¬(¬A3 → A4) → A5)",
        "prover9_expression": "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> terminated_grant(government_agency, research_lab))",
        "natural": "In case it is not the case that the negation of the research lab having funding for project alpha leads to the research lab receiving a grant from the government agency, then the government agency terminated the grant to the research lab."
      },
      {
        "id": "Rule43",
        "formal": "(¬(¬A3 → A4) → ¬A5)",
        "prover9_expression": "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> -terminated_grant(government_agency, research_lab))",
        "natural": "Assuming it is not the case that the negation of the research lab having funding for project alpha implies the research lab receives a grant from the government agency, then it is not the case that the government agency terminated the grant to the research lab."
      },
      {
        "id": "Rule44",
        "formal": "(¬(¬G → A16) → A17)",
        "prover9_expression": "(-(-approved_for_market(drug_x) -> qualifies_expedited_review(drug_x)) -> receives_priority_status(drug_x))",
        "natural": "Provided that it is not the case that the negation of drug X being approved for market leads to drug X qualifying for expedited review, then drug X receives priority status."
      },
      {
        "id": "Rule45",
        "formal": "(¬A3 → ¬A4)",
        "prover9_expression": "(-has_funding(research_lab, project_alpha) -> -receives_grant(research_lab, government_agency))",
        "natural": "In case it is not the case that the research lab has funding for project alpha, then it is not the case that the research lab receives a grant from the government agency."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A24",
        "prover9_expression": "has_collaboration(research_lab, company_a)",
        "natural": "The research lab has collaboration with company A."
      },
      {
        "id": "Fact2",
        "formal": "A26",
        "prover9_expression": "has_partnership(company_a, research_lab)",
        "natural": "Company A has a partnership with the research lab."
      },
      {
        "id": "Fact3",
        "formal": "A40",
        "prover9_expression": "has_gmp_certification(facility_a)",
        "natural": "Facility A has GMP certification."
      },
      {
        "id": "Fact4",
        "formal": "A43",
        "prover9_expression": "submits_dossier(company_a)",
        "natural": "Company A submits a dossier."
      },
      {
        "id": "Fact5",
        "formal": "A49",
        "prover9_expression": "receives_deficiency_letter(company_a)",
        "natural": "Company A receives a deficiency letter."
      },
      {
        "id": "Fact6",
        "formal": "A6",
        "prover9_expression": "passes_safety_test(drug_x)",
        "natural": "Drug X passes the safety test."
      },
      {
        "id": "Fact7",
        "formal": "A7",
        "prover9_expression": "passes_efficacy_test(drug_x)",
        "natural": "Drug X passes the efficacy test."
      },
      {
        "id": "Fact8",
        "formal": "¬A14",
        "prover9_expression": "-passes_toxicity_test(drug_x)",
        "natural": "It is not the case that drug X passes the toxicity test."
      },
      {
        "id": "Fact9",
        "formal": "¬A15",
        "prover9_expression": "-fails_toxicity_test(drug_x)",
        "natural": "It is not the case that drug X fails the toxicity test."
      },
      {
        "id": "Fact10",
        "formal": "¬A16",
        "prover9_expression": "-qualifies_expedited_review(drug_x)",
        "natural": "It is not the case that drug X qualifies for expedited review."
      },
      {
        "id": "Fact11",
        "formal": "¬A21",
        "prover9_expression": "-requests_extension(review_period)",
        "natural": "It is not the case that an extension of the review period is requested."
      },
      {
        "id": "Fact12",
        "formal": "¬A25",
        "prover9_expression": "-secures_investment(company_a)",
        "natural": "It is not the case that company A secures investment."
      },
      {
        "id": "Fact13",
        "formal": "¬A27",
        "prover9_expression": "-requires_retesting(drug_x)",
        "natural": "It is not the case that drug X requires retesting."
      },
      {
        "id": "Fact14",
        "formal": "¬A31",
        "prover9_expression": "-fails_manufacturing_audit(drug_x)",
        "natural": "It is not the case that drug X fails the manufacturing audit."
      },
      {
        "id": "Fact15",
        "formal": "¬A39",
        "prover9_expression": "-accepts_regulatory_submission(agency)",
        "natural": "It is not the case that the agency accepts the regulatory submission."
      },
      {
        "id": "Fact16",
        "formal": "¬A44",
        "prover9_expression": "-provides_clinical_data(company_b)",
        "natural": "It is not the case that company B provides clinical data."
      },
      {
        "id": "Fact17",
        "formal": "¬A47",
        "prover9_expression": "-requests_advisory_meeting(company_a)",
        "natural": "It is not the case that company A requests an advisory meeting."
      },
      {
        "id": "Fact18",
        "formal": "¬A50",
        "prover9_expression": "-faces_regulatory_sanctions(company_a)",
        "natural": "It is not the case that company A faces regulatory sanctions."
      },
      {
        "id": "Fact19",
        "formal": "¬A8",
        "prover9_expression": "-receives_fda_approval(drug_x)",
        "natural": "It is not the case that drug X receives FDA approval."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "approved_for_market(drug_x)",
    "natural": "Drug X is approved for market."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(-A3 -> A4) -> A5)",
            "(-(-A3 -> A4) -> -A5)"
          ],
          "conclusion": "(-A3 -> A4)",
          "natural": "If it is not the case that the research lab has funding for project alpha, then the research lab receives a grant from the government agency."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(-A3 -> A4)",
            "(-A3 -> -A4)"
          ],
          "conclusion": "A3",
          "natural": "The research lab has funding for project alpha."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A3 -> (A1 | A2))",
            "A3"
          ],
          "conclusion": "(A1 | A2)",
          "natural": "Either drug X is approved for clinical trial, or drug Y is approved for clinical trial."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A1 | A2)",
            "(A1 -> G)",
            "(A2 -> G)"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DE",
          "premises_used": [
            "(A12 | A13)",
            "(A12 -> (-(A9 -> A8) -> A11))",
            "(A13 -> (-(A9 -> A8) -> A11))"
          ],
          "conclusion": "(-(A9 -> A8) -> A11)",
          "natural": "If it is not the case that drug X completing phase III leads to drug X receiving FDA approval, then an appeal of the FDA decision is initiated."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A9 -> A8) -> A11)",
            "(-(A9 -> A8) -> -A11)"
          ],
          "conclusion": "(A9 -> A8)",
          "natural": "Provided that drug X completes phase III, then drug X receives FDA approval."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A9 -> A8)",
            "(A10 -> (A7 -> (A6 -> G)))",
            "(A9 | A10)"
          ],
          "conclusion": "(A8 | (A7 -> (A6 -> G)))",
          "natural": "Either drug X receives FDA approval, or if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A8 | (A7 -> (A6 -> G)))",
            "-A8"
          ],
          "conclusion": "(A7 -> (A6 -> G))",
          "natural": "If drug X passes the efficacy test, then assuming drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A7 -> (A6 -> G))",
            "A7"
          ],
          "conclusion": "(A6 -> G)",
          "natural": "Whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 6,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> G)",
            "A6"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A14 | G) -> A15)",
            "-A15"
          ],
          "conclusion": "(A14 | G)",
          "natural": "Drug X passes the toxicity test or drug X is approved for market."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A14 | G)",
            "-A14"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 4,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A21 | (A19 -> -A18))",
            "-A21"
          ],
          "conclusion": "(A19 -> -A18)",
          "natural": "If company A submits additional data, then it is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 2,
          "rule_applied": "DE",
          "premises_used": [
            "(A19 | A20)",
            "(A19 -> -A18)",
            "(A20 -> -A18)"
          ],
          "conclusion": "-A18",
          "natural": "It is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(A17 -> A18)",
            "-A18"
          ],
          "conclusion": "-A17",
          "natural": "It is not the case that drug X receives priority status."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-G -> A16) -> A17)",
            "-A17"
          ],
          "conclusion": "(-G -> A16)",
          "natural": "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A16)",
            "-A16"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 5,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            "(A24 -> (A23 -> A2))",
            "A24"
          ],
          "conclusion": "(A23 -> A2)",
          "natural": "Provided that the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial."
        },
        {
          "step_number": 2,
          "rule_applied": "CD",
          "premises_used": [
            "(A22 -> A1)",
            "(A23 -> A2)",
            "(A22 | A23)"
          ],
          "conclusion": "(A1 | A2)",
          "natural": "Either drug X is approved for clinical trial, or drug Y is approved for clinical trial."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A1 | A2)",
            "(A1 -> G)",
            "(A2 -> G)"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 6,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            "(A26 -> (A25 | A3))",
            "A26"
          ],
          "conclusion": "(A25 | A3)",
          "natural": "Either company A secures investment, or the research lab has funding for project alpha."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A25 | A3)",
            "-A25"
          ],
          "conclusion": "A3",
          "natural": "The research lab has funding for project alpha."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A3 -> (A1 | A2))",
            "A3"
          ],
          "conclusion": "(A1 | A2)",
          "natural": "Either drug X is approved for clinical trial, or drug Y is approved for clinical trial."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A1 | A2)",
            "(A1 -> G)",
            "(A2 -> G)"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 7,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 4,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(-(A6 -> G) -> A27) -> A28)",
            "(-(-(A6 -> G) -> A27) -> -A28)"
          ],
          "conclusion": "(-(A6 -> G) -> A27)",
          "natural": "In case it is not the case that drug X passing the safety test implies drug X is approved for market, then drug X requires retesting."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A6 -> G) -> A27)",
            "-A27"
          ],
          "conclusion": "(A6 -> G)",
          "natural": "Whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> G)",
            "A6"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 8,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 4,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A29 -> (A6 -> G)) -> A31)",
            "-A31"
          ],
          "conclusion": "(A29 -> (A6 -> G))",
          "natural": "If drug X meets manufacturing standards, then whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 2,
          "rule_applied": "DE",
          "premises_used": [
            "(A29 | A30)",
            "(A29 -> (A6 -> G))",
            "(A30 -> (A6 -> G))"
          ],
          "conclusion": "(A6 -> G)",
          "natural": "Whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> G)",
            "A6"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 9,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A34 -> A35)",
            "(A35 -> (A7 -> (A6 -> G)))"
          ],
          "conclusion": "(A34 -> (A7 -> (A6 -> G)))",
          "natural": "If drug X passes quality control, then assuming drug X passes the efficacy test, if drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A33 -> A34)",
            "(A34 -> (A7 -> (A6 -> G)))"
          ],
          "conclusion": "(A33 -> (A7 -> (A6 -> G)))",
          "natural": "Provided that drug Y completes the stability study, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A32 -> A8)",
            "(A33 -> (A7 -> (A6 -> G)))",
            "(A32 | A33)"
          ],
          "conclusion": "(A8 | (A7 -> (A6 -> G)))",
          "natural": "Either drug X receives FDA approval, or if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A8 | (A7 -> (A6 -> G)))",
            "-A8"
          ],
          "conclusion": "(A7 -> (A6 -> G))",
          "natural": "If drug X passes the efficacy test, then assuming drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A7 -> (A6 -> G))",
            "A7"
          ],
          "conclusion": "(A6 -> G)",
          "natural": "Whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 6,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> G)",
            "A6"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 10,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A39 | (-(A37 -> (A7 -> (A6 -> G))) -> A38))",
            "-A39"
          ],
          "conclusion": "(-(A37 -> (A7 -> (A6 -> G))) -> A38)",
          "natural": "Assuming it is not the case that drug Y completing the bioequivalence study implies drug X is approved for market under efficacy and safety, then reformulation of drug X is initiated."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A37 -> (A7 -> (A6 -> G))) -> A38)",
            "(-(A37 -> (A7 -> (A6 -> G))) -> -A38)"
          ],
          "conclusion": "(A37 -> (A7 -> (A6 -> G)))",
          "natural": "Assuming drug Y completes the bioequivalence study, then if drug X passes the efficacy test, provided that drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A36 -> A8)",
            "(A37 -> (A7 -> (A6 -> G)))",
            "(A36 | A37)"
          ],
          "conclusion": "(A8 | (A7 -> (A6 -> G)))",
          "natural": "Either drug X receives FDA approval, or if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A8 | (A7 -> (A6 -> G)))",
            "-A8"
          ],
          "conclusion": "(A7 -> (A6 -> G))",
          "natural": "If drug X passes the efficacy test, then assuming drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A7 -> (A6 -> G))",
            "A7"
          ],
          "conclusion": "(A6 -> G)",
          "natural": "Whenever drug X passes the safety test, drug X is approved for market."
        },
        {
          "step_number": 6,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> G)",
            "A6"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 11,
      "family_id": 3,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A40 -> A41)",
            "(A41 -> (A14 | G))"
          ],
          "conclusion": "(A40 -> (A14 | G))",
          "natural": "In case facility A has GMP certification, then either drug X passes the toxicity test or drug X is approved for market."
        },
        {
          "step_number": 2,
          "rule_applied": "MP",
          "premises_used": [
            "(A40 -> (A14 | G))",
            "A40"
          ],
          "conclusion": "(A14 | G)",
          "natural": "Drug X passes the toxicity test or drug X is approved for market."
        },
        {
          "step_number": 3,
          "rule_applied": "DS",
          "premises_used": [
            "(A14 | G)",
            "-A14"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 12,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            "(A43 -> A42)",
            "A43"
          ],
          "conclusion": "A42",
          "natural": "Company A provides clinical data."
        },
        {
          "step_number": 2,
          "rule_applied": "MP",
          "premises_used": [
            "(A42 -> -A18)",
            "A42"
          ],
          "conclusion": "-A18",
          "natural": "It is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(A17 -> A18)",
            "-A18"
          ],
          "conclusion": "-A17",
          "natural": "It is not the case that drug X receives priority status."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-G -> A16) -> A17)",
            "-A17"
          ],
          "conclusion": "(-G -> A16)",
          "natural": "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A16)",
            "-A16"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 13,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A47 | (A45 -> A44))",
            "-A47"
          ],
          "conclusion": "(A45 -> A44)",
          "natural": "Assuming company B submits a dossier, then company B provides clinical data."
        },
        {
          "step_number": 2,
          "rule_applied": "CD",
          "premises_used": [
            "(A45 -> A44)",
            "(A46 -> -A18)",
            "(A45 | A46)"
          ],
          "conclusion": "(A44 | -A18)",
          "natural": "Either company B provides clinical data, or approval of drug X is not delayed."
        },
        {
          "step_number": 3,
          "rule_applied": "DS",
          "premises_used": [
            "(A44 | -A18)",
            "-A44"
          ],
          "conclusion": "-A18",
          "natural": "It is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(A17 -> A18)",
            "-A18"
          ],
          "conclusion": "-A17",
          "natural": "It is not the case that drug X receives priority status."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-G -> A16) -> A17)",
            "-A17"
          ],
          "conclusion": "(-G -> A16)",
          "natural": "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A16)",
            "-A16"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    },
    {
      "id": 14,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A49 -> A48) -> A50)",
            "-A50"
          ],
          "conclusion": "(A49 -> A48)",
          "natural": "If company A receives a deficiency letter, then company A responds to the deficiency letter."
        },
        {
          "step_number": 2,
          "rule_applied": "MP",
          "premises_used": [
            "(A49 -> A48)",
            "A49"
          ],
          "conclusion": "A48",
          "natural": "Company A responds to the deficiency letter."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A48 -> (A19 -> -A18))",
            "A48"
          ],
          "conclusion": "(A19 -> -A18)",
          "natural": "If company A submits additional data, then it is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A19 | A20)",
            "(A19 -> -A18)",
            "(A20 -> -A18)"
          ],
          "conclusion": "-A18",
          "natural": "It is not the case that approval of drug X is delayed."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(A17 -> A18)",
            "-A18"
          ],
          "conclusion": "-A17",
          "natural": "It is not the case that drug X receives priority status."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-G -> A16) -> A17)",
            "-A17"
          ],
          "conclusion": "(-G -> A16)",
          "natural": "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review."
        },
        {
          "step_number": 7,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A16)",
            "-A16"
          ],
          "conclusion": "G",
          "natural": "Drug X is approved for market."
        }
      ]
    }
  ],
  "translations": {
    "domain_theme": "Pharmaceutical Manufacturing",
    "atomic_facts": {
      "A1": "approved(clinical_trial, drug_x)",
      "A2": "approved(clinical_trial, drug_y)",
      "A3": "has_funding(research_lab, project_alpha)",
      "A4": "receives_grant(research_lab, government_agency)",
      "A5": "terminated_grant(government_agency, research_lab)",
      "A6": "passes_safety_test(drug_x)",
      "A7": "passes_efficacy_test(drug_x)",
      "A8": "receives_fda_approval(drug_x)",
      "A9": "completes_phase_iii(drug_x)",
      "A10": "completes_phase_iii(drug_y)",
      "A11": "initiates_appeal(fda_decision)",
      "A12": "files_patent(company_a, drug_x)",
      "A13": "files_patent(company_b, drug_x)",
      "A14": "passes_toxicity_test(drug_x)",
      "A15": "fails_toxicity_test(drug_x)",
      "A16": "qualifies_expedited_review(drug_x)",
      "A17": "receives_priority_status(drug_x)",
      "A18": "delayed_approval(drug_x)",
      "A19": "submits_additional_data(company_a)",
      "A20": "submits_additional_data(company_b)",
      "A21": "requests_extension(review_period)",
      "A22": "positive_results(clinical_trial, drug_x)",
      "A23": "positive_results(clinical_trial, drug_y)",
      "A24": "has_collaboration(research_lab, company_a)",
      "A25": "secures_investment(company_a)",
      "A26": "has_partnership(company_a, research_lab)",
      "A27": "requires_retesting(drug_x)",
      "A28": "waives_retesting_requirement(drug_x)",
      "A29": "meets_manufacturing_standards(drug_x)",
      "A30": "meets_manufacturing_standards(drug_y)",
      "A31": "fails_manufacturing_audit(drug_x)",
      "A32": "completes_stability_study(drug_x)",
      "A33": "completes_stability_study(drug_y)",
      "A34": "passes_quality_control(drug_x)",
      "A35": "passes_quality_control(drug_y)",
      "A36": "completes_bioequivalence_study(drug_x)",
      "A37": "completes_bioequivalence_study(drug_y)",
      "A38": "initiates_reformulation(drug_x)",
      "A39": "accepts_regulatory_submission(agency)",
      "A40": "has_gmp_certification(facility_a)",
      "A41": "has_gmp_certification(facility_b)",
      "A42": "provides_clinical_data(company_a)",
      "A43": "submits_dossier(company_a)",
      "A44": "provides_clinical_data(company_b)",
      "A45": "submits_dossier(company_b)",
      "A46": "provides_additional_analysis(company_b)",
      "A47": "requests_advisory_meeting(company_a)",
      "A48": "responds_to_deficiency_letter(company_a)",
      "A49": "receives_deficiency_letter(company_a)",
      "A50": "faces_regulatory_sanctions(company_a)",
      "G": "approved_for_market(drug_x)"
    },
    "natural_facts": {
      "A1": "Drug X is approved for clinical trial.",
      "A2": "Drug Y is approved for clinical trial.",
      "A3": "The research lab has funding for project alpha.",
      "A4": "The research lab receives a grant from the government agency.",
      "A5": "The government agency terminated the grant to the research lab.",
      "A6": "Drug X passes the safety test.",
      "A7": "Drug X passes the efficacy test.",
      "A8": "Drug X receives FDA approval.",
      "A9": "Drug X completes phase III.",
      "A10": "Drug Y completes phase III.",
      "A11": "An appeal of the FDA decision is initiated.",
      "A12": "Company A files a patent for drug X.",
      "A13": "Company B files a patent for drug X.",
      "A14": "Drug X passes the toxicity test.",
      "A15": "Drug X fails the toxicity test.",
      "A16": "Drug X qualifies for expedited review.",
      "A17": "Drug X receives priority status.",
      "A18": "Approval of drug X is delayed.",
      "A19": "Company A submits additional data.",
      "A20": "Company B submits additional data.",
      "A21": "An extension of the review period is requested.",
      "A22": "The clinical trial yields positive results for drug X.",
      "A23": "The clinical trial yields positive results for drug Y.",
      "A24": "The research lab has collaboration with company A.",
      "A25": "Company A secures investment.",
      "A26": "Company A has a partnership with the research lab.",
      "A27": "Drug X requires retesting.",
      "A28": "The retesting requirement for drug X is waived.",
      "A29": "Drug X meets manufacturing standards.",
      "A30": "Drug Y meets manufacturing standards.",
      "A31": "Drug X fails the manufacturing audit.",
      "A32": "Drug X completes the stability study.",
      "A33": "Drug Y completes the stability study.",
      "A34": "Drug X passes quality control.",
      "A35": "Drug Y passes quality control.",
      "A36": "Drug X completes the bioequivalence study.",
      "A37": "Drug Y completes the bioequivalence study.",
      "A38": "Reformulation of drug X is initiated.",
      "A39": "The agency accepts the regulatory submission.",
      "A40": "Facility A has GMP certification.",
      "A41": "Facility B has GMP certification.",
      "A42": "Company A provides clinical data.",
      "A43": "Company A submits a dossier.",
      "A44": "Company B provides clinical data.",
      "A45": "Company B submits a dossier.",
      "A46": "Company B provides additional analysis.",
      "A47": "Company A requests an advisory meeting.",
      "A48": "Company A responds to the deficiency letter.",
      "A49": "Company A receives a deficiency letter.",
      "A50": "Company A faces regulatory sanctions.",
      "G": "Drug X is approved for market."
    },
    "prover9_expressions": [
      "(approved(clinical_trial, drug_x) -> approved_for_market(drug_x))",
      "(approved(clinical_trial, drug_x) | approved(clinical_trial, drug_y))",
      "(completes_phase_iii(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(files_patent(company_a, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
      "(files_patent(company_a, drug_x) | files_patent(company_b, drug_x))",
      "(files_patent(company_b, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
      "(passes_toxicity_test(drug_x) | approved_for_market(drug_x))",
      "(receives_priority_status(drug_x) -> delayed_approval(drug_x))",
      "(submits_additional_data(company_a) -> -delayed_approval(drug_x))",
      "(submits_additional_data(company_a) | submits_additional_data(company_b))",
      "(approved(clinical_trial, drug_y) -> approved_for_market(drug_x))",
      "(submits_additional_data(company_b) -> -delayed_approval(drug_x))",
      "(requests_extension(review_period) | (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
      "(positive_results(clinical_trial, drug_x) -> approved(clinical_trial, drug_x))",
      "(positive_results(clinical_trial, drug_x) | positive_results(clinical_trial, drug_y))",
      "(positive_results(clinical_trial, drug_y) -> approved(clinical_trial, drug_y))",
      "(has_collaboration(research_lab, company_a) -> (positive_results(clinical_trial, drug_y) -> approved(clinical_trial, drug_y)))",
      "(secures_investment(company_a) | has_funding(research_lab, project_alpha))",
      "(has_partnership(company_a, research_lab) -> (secures_investment(company_a) | has_funding(research_lab, project_alpha)))",
      "(meets_manufacturing_standards(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
      "(meets_manufacturing_standards(drug_x) | meets_manufacturing_standards(drug_y))",
      "(has_funding(research_lab, project_alpha) -> (approved(clinical_trial, drug_x) | approved(clinical_trial, drug_y)))",
      "(meets_manufacturing_standards(drug_y) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
      "(completes_stability_study(drug_x) -> receives_fda_approval(drug_x))",
      "(completes_stability_study(drug_x) | completes_stability_study(drug_y))",
      "(completes_stability_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(completes_stability_study(drug_y) -> passes_quality_control(drug_x))",
      "(passes_quality_control(drug_x) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(passes_quality_control(drug_x) -> passes_quality_control(drug_y))",
      "(passes_quality_control(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(completes_bioequivalence_study(drug_x) -> receives_fda_approval(drug_x))",
      "(completes_bioequivalence_study(drug_x) | completes_bioequivalence_study(drug_y))",
      "(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(accepts_regulatory_submission(agency) | (-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> initiates_reformulation(drug_x)))",
      "(has_gmp_certification(facility_a) -> (passes_toxicity_test(drug_x) | approved_for_market(drug_x)))",
      "(has_gmp_certification(facility_a) -> has_gmp_certification(facility_b))",
      "(has_gmp_certification(facility_b) -> (passes_toxicity_test(drug_x) | approved_for_market(drug_x)))",
      "(provides_clinical_data(company_a) -> -delayed_approval(drug_x))",
      "(submits_dossier(company_a) -> provides_clinical_data(company_a))",
      "(provides_clinical_data(company_b) | -delayed_approval(drug_x))",
      "(submits_dossier(company_b) -> provides_clinical_data(company_b))",
      "(submits_dossier(company_b) | provides_additional_analysis(company_b))",
      "(provides_additional_analysis(company_b) -> -delayed_approval(drug_x))",
      "(requests_advisory_meeting(company_a) | (submits_dossier(company_b) -> provides_clinical_data(company_b)))",
      "(responds_to_deficiency_letter(company_a) -> (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
      "(receives_deficiency_letter(company_a) -> responds_to_deficiency_letter(company_a))",
      "(passes_safety_test(drug_x) -> approved_for_market(drug_x))",
      "(passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
      "(receives_fda_approval(drug_x) | (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
      "(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x))",
      "(completes_phase_iii(drug_x) | completes_phase_iii(drug_y))",
      "(-(passes_toxicity_test(drug_x) | approved_for_market(drug_x)) -> fails_toxicity_test(drug_x))",
      "(-(meets_manufacturing_standards(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))) -> fails_manufacturing_audit(drug_x))",
      "(-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> initiates_reformulation(drug_x))",
      "(-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> -initiates_reformulation(drug_x))",
      "(-(receives_deficiency_letter(company_a) -> responds_to_deficiency_letter(company_a)) -> faces_regulatory_sanctions(company_a))",
      "(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x))",
      "(-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision))",
      "(-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> -initiates_appeal(fda_decision))",
      "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> waives_retesting_requirement(drug_x))",
      "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> -waives_retesting_requirement(drug_x))",
      "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> terminated_grant(government_agency, research_lab))",
      "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> -terminated_grant(government_agency, research_lab))",
      "(-(-approved_for_market(drug_x) -> qualifies_expedited_review(drug_x)) -> receives_priority_status(drug_x))",
      "(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency))",
      "(-has_funding(research_lab, project_alpha) -> -receives_grant(research_lab, government_agency))",
      "(-approved_for_market(drug_x) -> qualifies_expedited_review(drug_x))",
      "has_collaboration(research_lab, company_a)",
      "has_partnership(company_a, research_lab)",
      "has_funding(research_lab, project_alpha)",
      "has_gmp_certification(facility_a)",
      "provides_clinical_data(company_a)",
      "submits_dossier(company_a)",
      "responds_to_deficiency_letter(company_a)",
      "receives_deficiency_letter(company_a)",
      "passes_safety_test(drug_x)",
      "passes_efficacy_test(drug_x)",
      "approved_for_market(drug_x)",
      "-passes_toxicity_test(drug_x)",
      "-fails_toxicity_test(drug_x)",
      "-qualifies_expedited_review(drug_x)",
      "-receives_priority_status(drug_x)",
      "-delayed_approval(drug_x)",
      "-requests_extension(review_period)",
      "-secures_investment(company_a)",
      "-requires_retesting(drug_x)",
      "-fails_manufacturing_audit(drug_x)",
      "-accepts_regulatory_submission(agency)",
      "-provides_clinical_data(company_b)",
      "-requests_advisory_meeting(company_a)",
      "-faces_regulatory_sanctions(company_a)",
      "-receives_fda_approval(drug_x)"
    ],
    "natural_expressions": [
      "If drug X is approved for clinical trial, then drug X is approved for market.",
      "Either drug X is approved for clinical trial, or drug Y is approved for clinical trial.",
      "Provided that drug Y completes phase III, if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market.",
      "In case company A files a patent for drug X, then if it is not the case that drug X completing phase III leads to drug X receiving FDA approval, an appeal of the FDA decision is initiated.",
      "Either company A files a patent for drug X, or company B files a patent for drug X.",
      "Assuming company B files a patent for drug X, then if it is not the case that drug X completing phase III implies drug X receives FDA approval, an appeal of the FDA decision is initiated.",
      "Drug X passes the toxicity test or drug X is approved for market.",
      "Whenever drug X receives priority status, approval of drug X is delayed.",
      "If company A submits additional data, then it is not the case that approval of drug X is delayed.",
      "Company A submits additional data or company B submits additional data.",
      "Provided that drug Y is approved for clinical trial, drug X is approved for market.",
      "In case company B submits additional data, then approval of drug X is not delayed.",
      "Either an extension of the review period is requested, or if company A submits additional data, then approval of drug X is not delayed.",
      "If the clinical trial yields positive results for drug X, then drug X is approved for clinical trial.",
      "The clinical trial yields positive results for drug X or the clinical trial yields positive results for drug Y.",
      "Provided that the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial.",
      "Assuming the research lab has collaboration with company A, then if the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial.",
      "Either company A secures investment, or the research lab has funding for project alpha.",
      "In case company A has a partnership with the research lab, then either company A secures investment or the research lab has funding for project alpha.",
      "If drug X meets manufacturing standards, then whenever drug X passes the safety test, drug X is approved for market.",
      "Drug X meets manufacturing standards or drug Y meets manufacturing standards.",
      "Provided that the research lab has funding for project alpha, then either drug X is approved for clinical trial or drug Y is approved for clinical trial.",
      "Assuming drug Y meets manufacturing standards, then if drug X passes the safety test, drug X is approved for market.",
      "If drug X completes the stability study, then drug X receives FDA approval.",
      "Either drug X completes the stability study, or drug Y completes the stability study.",
      "Provided that drug Y completes the stability study, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market.",
      "In case drug Y completes the stability study, then drug X passes quality control.",
      "If drug X passes quality control, then assuming drug X passes the efficacy test, if drug X passes the safety test, drug X is approved for market.",
      "Whenever drug X passes quality control, drug Y passes quality control.",
      "Provided that drug Y passes quality control, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market.",
      "If drug X completes the bioequivalence study, then drug X receives FDA approval.",
      "Either drug X completes the bioequivalence study, or drug Y completes the bioequivalence study.",
      "Assuming drug Y completes the bioequivalence study, then if drug X passes the efficacy test, provided that drug X passes the safety test, drug X is approved for market.",
      "Either the agency accepts the regulatory submission, or if it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then reformulation of drug X is initiated.",
      "In case facility A has GMP certification, then either drug X passes the toxicity test or drug X is approved for market.",
      "If facility A has GMP certification, then facility B has GMP certification.",
      "Provided that facility B has GMP certification, then drug X passes the toxicity test or drug X is approved for market.",
      "Whenever company A provides clinical data, then it is not the case that approval of drug X is delayed.",
      "If company A submits a dossier, then company A provides clinical data.",
      "Either company B provides clinical data, or approval of drug X is not delayed.",
      "Assuming company B submits a dossier, then company B provides clinical data.",
      "Company B submits a dossier or company B provides additional analysis.",
      "In case company B provides additional analysis, then approval of drug X is not delayed.",
      "Either company A requests an advisory meeting, or if company B submits a dossier, then company B provides clinical data.",
      "Provided that company A responds to the deficiency letter, then if company A submits additional data, approval of drug X is not delayed.",
      "If company A receives a deficiency letter, then company A responds to the deficiency letter.",
      "Whenever drug X passes the safety test, drug X is approved for market.",
      "If drug X passes the efficacy test, then assuming drug X passes the safety test, drug X is approved for market.",
      "Either drug X receives FDA approval, or if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market.",
      "Provided that drug X completes phase III, then drug X receives FDA approval.",
      "Drug X completes phase III or drug Y completes phase III.",
      "If it is not the case that drug X passes the toxicity test or drug X is approved for market, then drug X fails the toxicity test.",
      "In case it is not the case that drug X meeting manufacturing standards leads to drug X being approved for market under safety, then drug X fails the manufacturing audit.",
      "Assuming it is not the case that drug Y completing the bioequivalence study implies drug X is approved for market under efficacy and safety, then reformulation of drug X is initiated.",
      "If it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then it is not the case that reformulation of drug X is initiated.",
      "Provided that it is not the case that company A receiving a deficiency letter leads to company A responding to the deficiency letter, then company A faces regulatory sanctions.",
      "In case it is not the case that drug X passing the safety test implies drug X is approved for market, then drug X requires retesting.",
      "If it is not the case that drug X completing phase III leads to drug X receiving FDA approval, then an appeal of the FDA decision is initiated.",
      "Assuming it is not the case that drug X completing phase III implies drug X receives FDA approval, then it is not the case that an appeal of the FDA decision is initiated.",
      "Provided that it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then the retesting requirement for drug X is waived.",
      "If it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then it is not the case that the retesting requirement for drug X is waived.",
      "In case it is not the case that the negation of the research lab having funding for project alpha leads to the research lab receiving a grant from the government agency, then the government agency terminated the grant to the research lab.",
      "Assuming it is not the case that the negation of the research lab having funding for project alpha implies the research lab receives a grant from the government agency, then it is not the case that the government agency terminated the grant to the research lab.",
      "Provided that it is not the case that the negation of drug X being approved for market leads to drug X qualifying for expedited review, then drug X receives priority status.",
      "If it is not the case that the research lab has funding for project alpha, then the research lab receives a grant from the government agency.",
      "In case it is not the case that the research lab has funding for project alpha, then it is not the case that the research lab receives a grant from the government agency.",
      "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review.",
      "The research lab has collaboration with company A.",
      "Company A has a partnership with the research lab.",
      "The research lab has funding for project alpha.",
      "Facility A has GMP certification.",
      "Company A provides clinical data.",
      "Company A submits a dossier.",
      "Company A responds to the deficiency letter.",
      "Company A receives a deficiency letter.",
      "Drug X passes the safety test.",
      "Drug X passes the efficacy test.",
      "Drug X is approved for market.",
      "It is not the case that drug X passes the toxicity test.",
      "It is not the case that drug X fails the toxicity test.",
      "It is not the case that drug X qualifies for expedited review.",
      "It is not the case that drug X receives priority status.",
      "It is not the case that approval of drug X is delayed.",
      "It is not the case that an extension of the review period is requested.",
      "It is not the case that company A secures investment.",
      "It is not the case that drug X requires retesting.",
      "It is not the case that drug X fails the manufacturing audit.",
      "It is not the case that the agency accepts the regulatory submission.",
      "It is not the case that company B provides clinical data.",
      "It is not the case that company A requests an advisory meeting.",
      "It is not the case that company A faces regulatory sanctions.",
      "It is not the case that drug X receives FDA approval."
    ],
    "node_mappings": {
      "(A1 → G)": {
        "formal": "(A1 → G)",
        "prover9": "(A1 -> G)",
        "prover9_expression": "(approved(clinical_trial, drug_x) -> approved_for_market(drug_x))",
        "natural": "If drug X is approved for clinical trial, then drug X is approved for market."
      },
      "(A1 ∨ A2)": {
        "formal": "(A1 ∨ A2)",
        "prover9": "(A1 | A2)",
        "prover9_expression": "(approved(clinical_trial, drug_x) | approved(clinical_trial, drug_y))",
        "natural": "Either drug X is approved for clinical trial, or drug Y is approved for clinical trial."
      },
      "(A10 → (A7 → (A6 → G)))": {
        "formal": "(A10 → (A7 → (A6 → G)))",
        "prover9": "(A10 -> (A7 -> (A6 -> G)))",
        "prover9_expression": "(completes_phase_iii(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Provided that drug Y completes phase III, if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A12 → (¬(A9 → A8) → A11))": {
        "formal": "(A12 → (¬(A9 → A8) → A11))",
        "prover9": "(A12 -> (-(A9 -> A8) -> A11))",
        "prover9_expression": "(files_patent(company_a, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
        "natural": "In case company A files a patent for drug X, then if it is not the case that drug X completing phase III leads to drug X receiving FDA approval, an appeal of the FDA decision is initiated."
      },
      "(A12 ∨ A13)": {
        "formal": "(A12 ∨ A13)",
        "prover9": "(A12 | A13)",
        "prover9_expression": "(files_patent(company_a, drug_x) | files_patent(company_b, drug_x))",
        "natural": "Either company A files a patent for drug X, or company B files a patent for drug X."
      },
      "(A13 → (¬(A9 → A8) → A11))": {
        "formal": "(A13 → (¬(A9 → A8) → A11))",
        "prover9": "(A13 -> (-(A9 -> A8) -> A11))",
        "prover9_expression": "(files_patent(company_b, drug_x) -> (-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision)))",
        "natural": "Assuming company B files a patent for drug X, then if it is not the case that drug X completing phase III implies drug X receives FDA approval, an appeal of the FDA decision is initiated."
      },
      "(A14 ∨ G)": {
        "formal": "(A14 ∨ G)",
        "prover9": "(A14 | G)",
        "prover9_expression": "(passes_toxicity_test(drug_x) | approved_for_market(drug_x))",
        "natural": "Drug X passes the toxicity test or drug X is approved for market."
      },
      "(A17 → A18)": {
        "formal": "(A17 → A18)",
        "prover9": "(A17 -> A18)",
        "prover9_expression": "(receives_priority_status(drug_x) -> delayed_approval(drug_x))",
        "natural": "Whenever drug X receives priority status, approval of drug X is delayed."
      },
      "(A19 → ¬A18)": {
        "formal": "(A19 → ¬A18)",
        "prover9": "(A19 -> -A18)",
        "prover9_expression": "(submits_additional_data(company_a) -> -delayed_approval(drug_x))",
        "natural": "If company A submits additional data, then it is not the case that approval of drug X is delayed."
      },
      "(A19 ∨ A20)": {
        "formal": "(A19 ∨ A20)",
        "prover9": "(A19 | A20)",
        "prover9_expression": "(submits_additional_data(company_a) | submits_additional_data(company_b))",
        "natural": "Company A submits additional data or company B submits additional data."
      },
      "(A2 → G)": {
        "formal": "(A2 → G)",
        "prover9": "(A2 -> G)",
        "prover9_expression": "(approved(clinical_trial, drug_y) -> approved_for_market(drug_x))",
        "natural": "Provided that drug Y is approved for clinical trial, drug X is approved for market."
      },
      "(A20 → ¬A18)": {
        "formal": "(A20 → ¬A18)",
        "prover9": "(A20 -> -A18)",
        "prover9_expression": "(submits_additional_data(company_b) -> -delayed_approval(drug_x))",
        "natural": "In case company B submits additional data, then approval of drug X is not delayed."
      },
      "(A21 ∨ (A19 → ¬A18))": {
        "formal": "(A21 ∨ (A19 → ¬A18))",
        "prover9": "(A21 | (A19 -> -A18))",
        "prover9_expression": "(requests_extension(review_period) | (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
        "natural": "Either an extension of the review period is requested, or if company A submits additional data, then approval of drug X is not delayed."
      },
      "(A22 → A1)": {
        "formal": "(A22 → A1)",
        "prover9": "(A22 -> A1)",
        "prover9_expression": "(positive_results(clinical_trial, drug_x) -> approved(clinical_trial, drug_x))",
        "natural": "If the clinical trial yields positive results for drug X, then drug X is approved for clinical trial."
      },
      "(A22 ∨ A23)": {
        "formal": "(A22 ∨ A23)",
        "prover9": "(A22 | A23)",
        "prover9_expression": "(positive_results(clinical_trial, drug_x) | positive_results(clinical_trial, drug_y))",
        "natural": "The clinical trial yields positive results for drug X or the clinical trial yields positive results for drug Y."
      },
      "(A23 → A2)": {
        "formal": "(A23 → A2)",
        "prover9": "(A23 -> A2)",
        "prover9_expression": "(positive_results(clinical_trial, drug_y) -> approved(clinical_trial, drug_y))",
        "natural": "Provided that the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial."
      },
      "(A24 → (A23 → A2))": {
        "formal": "(A24 → (A23 → A2))",
        "prover9": "(A24 -> (A23 -> A2))",
        "prover9_expression": "(has_collaboration(research_lab, company_a) -> (positive_results(clinical_trial, drug_y) -> approved(clinical_trial, drug_y)))",
        "natural": "Assuming the research lab has collaboration with company A, then if the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial."
      },
      "(A25 ∨ A3)": {
        "formal": "(A25 ∨ A3)",
        "prover9": "(A25 | A3)",
        "prover9_expression": "(secures_investment(company_a) | has_funding(research_lab, project_alpha))",
        "natural": "Either company A secures investment, or the research lab has funding for project alpha."
      },
      "(A26 → (A25 ∨ A3))": {
        "formal": "(A26 → (A25 ∨ A3))",
        "prover9": "(A26 -> (A25 | A3))",
        "prover9_expression": "(has_partnership(company_a, research_lab) -> (secures_investment(company_a) | has_funding(research_lab, project_alpha)))",
        "natural": "In case company A has a partnership with the research lab, then either company A secures investment or the research lab has funding for project alpha."
      },
      "(A29 → (A6 → G))": {
        "formal": "(A29 → (A6 → G))",
        "prover9": "(A29 -> (A6 -> G))",
        "prover9_expression": "(meets_manufacturing_standards(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
        "natural": "If drug X meets manufacturing standards, then whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A29 ∨ A30)": {
        "formal": "(A29 ∨ A30)",
        "prover9": "(A29 | A30)",
        "prover9_expression": "(meets_manufacturing_standards(drug_x) | meets_manufacturing_standards(drug_y))",
        "natural": "Drug X meets manufacturing standards or drug Y meets manufacturing standards."
      },
      "(A3 → (A1 ∨ A2))": {
        "formal": "(A3 → (A1 ∨ A2))",
        "prover9": "(A3 -> (A1 | A2))",
        "prover9_expression": "(has_funding(research_lab, project_alpha) -> (approved(clinical_trial, drug_x) | approved(clinical_trial, drug_y)))",
        "natural": "Provided that the research lab has funding for project alpha, then either drug X is approved for clinical trial or drug Y is approved for clinical trial."
      },
      "(A30 → (A6 → G))": {
        "formal": "(A30 → (A6 → G))",
        "prover9": "(A30 -> (A6 -> G))",
        "prover9_expression": "(meets_manufacturing_standards(drug_y) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
        "natural": "Assuming drug Y meets manufacturing standards, then if drug X passes the safety test, drug X is approved for market."
      },
      "(A32 → A8)": {
        "formal": "(A32 → A8)",
        "prover9": "(A32 -> A8)",
        "prover9_expression": "(completes_stability_study(drug_x) -> receives_fda_approval(drug_x))",
        "natural": "If drug X completes the stability study, then drug X receives FDA approval."
      },
      "(A32 ∨ A33)": {
        "formal": "(A32 ∨ A33)",
        "prover9": "(A32 | A33)",
        "prover9_expression": "(completes_stability_study(drug_x) | completes_stability_study(drug_y))",
        "natural": "Either drug X completes the stability study, or drug Y completes the stability study."
      },
      "(A33 → (A7 → (A6 → G)))": {
        "formal": "(A33 → (A7 → (A6 → G)))",
        "prover9": "(A33 -> (A7 -> (A6 -> G)))",
        "prover9_expression": "(completes_stability_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Provided that drug Y completes the stability study, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A33 → A34)": {
        "formal": "(A33 → A34)",
        "prover9": "(A33 -> A34)",
        "prover9_expression": "(completes_stability_study(drug_y) -> passes_quality_control(drug_x))",
        "natural": "In case drug Y completes the stability study, then drug X passes quality control."
      },
      "(A34 → (A7 → (A6 → G)))": {
        "formal": "(A34 → (A7 → (A6 → G)))",
        "prover9": "(A34 -> (A7 -> (A6 -> G)))",
        "prover9_expression": "(passes_quality_control(drug_x) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "If drug X passes quality control, then assuming drug X passes the efficacy test, if drug X passes the safety test, drug X is approved for market."
      },
      "(A34 → A35)": {
        "formal": "(A34 → A35)",
        "prover9": "(A34 -> A35)",
        "prover9_expression": "(passes_quality_control(drug_x) -> passes_quality_control(drug_y))",
        "natural": "Whenever drug X passes quality control, drug Y passes quality control."
      },
      "(A35 → (A7 → (A6 → G)))": {
        "formal": "(A35 → (A7 → (A6 → G)))",
        "prover9": "(A35 -> (A7 -> (A6 -> G)))",
        "prover9_expression": "(passes_quality_control(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Provided that drug Y passes quality control, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A36 → A8)": {
        "formal": "(A36 → A8)",
        "prover9": "(A36 -> A8)",
        "prover9_expression": "(completes_bioequivalence_study(drug_x) -> receives_fda_approval(drug_x))",
        "natural": "If drug X completes the bioequivalence study, then drug X receives FDA approval."
      },
      "(A36 ∨ A37)": {
        "formal": "(A36 ∨ A37)",
        "prover9": "(A36 | A37)",
        "prover9_expression": "(completes_bioequivalence_study(drug_x) | completes_bioequivalence_study(drug_y))",
        "natural": "Either drug X completes the bioequivalence study, or drug Y completes the bioequivalence study."
      },
      "(A37 → (A7 → (A6 → G)))": {
        "formal": "(A37 → (A7 → (A6 → G)))",
        "prover9": "(A37 -> (A7 -> (A6 -> G)))",
        "prover9_expression": "(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Assuming drug Y completes the bioequivalence study, then if drug X passes the efficacy test, provided that drug X passes the safety test, drug X is approved for market."
      },
      "(A39 ∨ (¬(A37 → (A7 → (A6 → G))) → A38))": {
        "formal": "(A39 ∨ (¬(A37 → (A7 → (A6 → G))) → A38))",
        "prover9": "(A39 | (-(A37 -> (A7 -> (A6 -> G))) -> A38))",
        "prover9_expression": "(accepts_regulatory_submission(agency) | (-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> initiates_reformulation(drug_x)))",
        "natural": "Either the agency accepts the regulatory submission, or if it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then reformulation of drug X is initiated."
      },
      "(A40 → (A14 ∨ G))": {
        "formal": "(A40 → (A14 ∨ G))",
        "prover9": "(A40 -> (A14 | G))",
        "prover9_expression": "(has_gmp_certification(facility_a) -> (passes_toxicity_test(drug_x) | approved_for_market(drug_x)))",
        "natural": "In case facility A has GMP certification, then either drug X passes the toxicity test or drug X is approved for market."
      },
      "(A40 → A41)": {
        "formal": "(A40 → A41)",
        "prover9": "(A40 -> A41)",
        "prover9_expression": "(has_gmp_certification(facility_a) -> has_gmp_certification(facility_b))",
        "natural": "If facility A has GMP certification, then facility B has GMP certification."
      },
      "(A41 → (A14 ∨ G))": {
        "formal": "(A41 → (A14 ∨ G))",
        "prover9": "(A41 -> (A14 | G))",
        "prover9_expression": "(has_gmp_certification(facility_b) -> (passes_toxicity_test(drug_x) | approved_for_market(drug_x)))",
        "natural": "Provided that facility B has GMP certification, then drug X passes the toxicity test or drug X is approved for market."
      },
      "(A42 → ¬A18)": {
        "formal": "(A42 → ¬A18)",
        "prover9": "(A42 -> -A18)",
        "prover9_expression": "(provides_clinical_data(company_a) -> -delayed_approval(drug_x))",
        "natural": "Whenever company A provides clinical data, then it is not the case that approval of drug X is delayed."
      },
      "(A43 → A42)": {
        "formal": "(A43 → A42)",
        "prover9": "(A43 -> A42)",
        "prover9_expression": "(submits_dossier(company_a) -> provides_clinical_data(company_a))",
        "natural": "If company A submits a dossier, then company A provides clinical data."
      },
      "(A44 ∨ ¬A18)": {
        "formal": "(A44 ∨ ¬A18)",
        "prover9": "(A44 | -A18)",
        "prover9_expression": "(provides_clinical_data(company_b) | -delayed_approval(drug_x))",
        "natural": "Either company B provides clinical data, or approval of drug X is not delayed."
      },
      "(A45 → A44)": {
        "formal": "(A45 → A44)",
        "prover9": "(A45 -> A44)",
        "prover9_expression": "(submits_dossier(company_b) -> provides_clinical_data(company_b))",
        "natural": "Assuming company B submits a dossier, then company B provides clinical data."
      },
      "(A45 ∨ A46)": {
        "formal": "(A45 ∨ A46)",
        "prover9": "(A45 | A46)",
        "prover9_expression": "(submits_dossier(company_b) | provides_additional_analysis(company_b))",
        "natural": "Company B submits a dossier or company B provides additional analysis."
      },
      "(A46 → ¬A18)": {
        "formal": "(A46 → ¬A18)",
        "prover9": "(A46 -> -A18)",
        "prover9_expression": "(provides_additional_analysis(company_b) -> -delayed_approval(drug_x))",
        "natural": "In case company B provides additional analysis, then approval of drug X is not delayed."
      },
      "(A47 ∨ (A45 → A44))": {
        "formal": "(A47 ∨ (A45 → A44))",
        "prover9": "(A47 | (A45 -> A44))",
        "prover9_expression": "(requests_advisory_meeting(company_a) | (submits_dossier(company_b) -> provides_clinical_data(company_b)))",
        "natural": "Either company A requests an advisory meeting, or if company B submits a dossier, then company B provides clinical data."
      },
      "(A48 → (A19 → ¬A18))": {
        "formal": "(A48 → (A19 → ¬A18))",
        "prover9": "(A48 -> (A19 -> -A18))",
        "prover9_expression": "(responds_to_deficiency_letter(company_a) -> (submits_additional_data(company_a) -> -delayed_approval(drug_x)))",
        "natural": "Provided that company A responds to the deficiency letter, then if company A submits additional data, approval of drug X is not delayed."
      },
      "(A49 → A48)": {
        "formal": "(A49 → A48)",
        "prover9": "(A49 -> A48)",
        "prover9_expression": "(receives_deficiency_letter(company_a) -> responds_to_deficiency_letter(company_a))",
        "natural": "If company A receives a deficiency letter, then company A responds to the deficiency letter."
      },
      "(A6 → G)": {
        "formal": "(A6 → G)",
        "prover9": "(A6 -> G)",
        "prover9_expression": "(passes_safety_test(drug_x) -> approved_for_market(drug_x))",
        "natural": "Whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A7 → (A6 → G))": {
        "formal": "(A7 → (A6 → G))",
        "prover9": "(A7 -> (A6 -> G))",
        "prover9_expression": "(passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))",
        "natural": "If drug X passes the efficacy test, then assuming drug X passes the safety test, drug X is approved for market."
      },
      "(A8 ∨ (A7 → (A6 → G)))": {
        "formal": "(A8 ∨ (A7 → (A6 → G)))",
        "prover9": "(A8 | (A7 -> (A6 -> G)))",
        "prover9_expression": "(receives_fda_approval(drug_x) | (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))))",
        "natural": "Either drug X receives FDA approval, or if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market."
      },
      "(A9 → A8)": {
        "formal": "(A9 → A8)",
        "prover9": "(A9 -> A8)",
        "prover9_expression": "(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x))",
        "natural": "Provided that drug X completes phase III, then drug X receives FDA approval."
      },
      "(A9 ∨ A10)": {
        "formal": "(A9 ∨ A10)",
        "prover9": "(A9 | A10)",
        "prover9_expression": "(completes_phase_iii(drug_x) | completes_phase_iii(drug_y))",
        "natural": "Drug X completes phase III or drug Y completes phase III."
      },
      "(¬(A14 ∨ G) → A15)": {
        "formal": "(¬(A14 ∨ G) → A15)",
        "prover9": "(-(A14 | G) -> A15)",
        "prover9_expression": "(-(passes_toxicity_test(drug_x) | approved_for_market(drug_x)) -> fails_toxicity_test(drug_x))",
        "natural": "If it is not the case that drug X passes the toxicity test or drug X is approved for market, then drug X fails the toxicity test."
      },
      "(¬(A29 → (A6 → G)) → A31)": {
        "formal": "(¬(A29 → (A6 → G)) → A31)",
        "prover9": "(-(A29 -> (A6 -> G)) -> A31)",
        "prover9_expression": "(-(meets_manufacturing_standards(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x))) -> fails_manufacturing_audit(drug_x))",
        "natural": "In case it is not the case that drug X meeting manufacturing standards leads to drug X being approved for market under safety, then drug X fails the manufacturing audit."
      },
      "(¬(A37 → (A7 → (A6 → G))) → A38)": {
        "formal": "(¬(A37 → (A7 → (A6 → G))) → A38)",
        "prover9": "(-(A37 -> (A7 -> (A6 -> G))) -> A38)",
        "prover9_expression": "(-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> initiates_reformulation(drug_x))",
        "natural": "Assuming it is not the case that drug Y completing the bioequivalence study implies drug X is approved for market under efficacy and safety, then reformulation of drug X is initiated."
      },
      "(¬(A37 → (A7 → (A6 → G))) → ¬A38)": {
        "formal": "(¬(A37 → (A7 → (A6 → G))) → ¬A38)",
        "prover9": "(-(A37 -> (A7 -> (A6 -> G))) -> -A38)",
        "prover9_expression": "(-(completes_bioequivalence_study(drug_y) -> (passes_efficacy_test(drug_x) -> (passes_safety_test(drug_x) -> approved_for_market(drug_x)))) -> -initiates_reformulation(drug_x))",
        "natural": "If it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then it is not the case that reformulation of drug X is initiated."
      },
      "(¬(A49 → A48) → A50)": {
        "formal": "(¬(A49 → A48) → A50)",
        "prover9": "(-(A49 -> A48) -> A50)",
        "prover9_expression": "(-(receives_deficiency_letter(company_a) -> responds_to_deficiency_letter(company_a)) -> faces_regulatory_sanctions(company_a))",
        "natural": "Provided that it is not the case that company A receiving a deficiency letter leads to company A responding to the deficiency letter, then company A faces regulatory sanctions."
      },
      "(¬(A6 → G) → A27)": {
        "formal": "(¬(A6 → G) → A27)",
        "prover9": "(-(A6 -> G) -> A27)",
        "prover9_expression": "(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x))",
        "natural": "In case it is not the case that drug X passing the safety test implies drug X is approved for market, then drug X requires retesting."
      },
      "(¬(A9 → A8) → A11)": {
        "formal": "(¬(A9 → A8) → A11)",
        "prover9": "(-(A9 -> A8) -> A11)",
        "prover9_expression": "(-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> initiates_appeal(fda_decision))",
        "natural": "If it is not the case that drug X completing phase III leads to drug X receiving FDA approval, then an appeal of the FDA decision is initiated."
      },
      "(¬(A9 → A8) → ¬A11)": {
        "formal": "(¬(A9 → A8) → ¬A11)",
        "prover9": "(-(A9 -> A8) -> -A11)",
        "prover9_expression": "(-(completes_phase_iii(drug_x) -> receives_fda_approval(drug_x)) -> -initiates_appeal(fda_decision))",
        "natural": "Assuming it is not the case that drug X completing phase III implies drug X receives FDA approval, then it is not the case that an appeal of the FDA decision is initiated."
      },
      "(¬(¬(A6 → G) → A27) → A28)": {
        "formal": "(¬(¬(A6 → G) → A27) → A28)",
        "prover9": "(-(-(A6 -> G) -> A27) -> A28)",
        "prover9_expression": "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> waives_retesting_requirement(drug_x))",
        "natural": "Provided that it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then the retesting requirement for drug X is waived."
      },
      "(¬(¬(A6 → G) → A27) → ¬A28)": {
        "formal": "(¬(¬(A6 → G) → A27) → ¬A28)",
        "prover9": "(-(-(A6 -> G) -> A27) -> -A28)",
        "prover9_expression": "(-(-(passes_safety_test(drug_x) -> approved_for_market(drug_x)) -> requires_retesting(drug_x)) -> -waives_retesting_requirement(drug_x))",
        "natural": "If it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then it is not the case that the retesting requirement for drug X is waived."
      },
      "(¬(¬A3 → A4) → A5)": {
        "formal": "(¬(¬A3 → A4) → A5)",
        "prover9": "(-(-A3 -> A4) -> A5)",
        "prover9_expression": "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> terminated_grant(government_agency, research_lab))",
        "natural": "In case it is not the case that the negation of the research lab having funding for project alpha leads to the research lab receiving a grant from the government agency, then the government agency terminated the grant to the research lab."
      },
      "(¬(¬A3 → A4) → ¬A5)": {
        "formal": "(¬(¬A3 → A4) → ¬A5)",
        "prover9": "(-(-A3 -> A4) -> -A5)",
        "prover9_expression": "(-(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency)) -> -terminated_grant(government_agency, research_lab))",
        "natural": "Assuming it is not the case that the negation of the research lab having funding for project alpha implies the research lab receives a grant from the government agency, then it is not the case that the government agency terminated the grant to the research lab."
      },
      "(¬(¬G → A16) → A17)": {
        "formal": "(¬(¬G → A16) → A17)",
        "prover9": "(-(-G -> A16) -> A17)",
        "prover9_expression": "(-(-approved_for_market(drug_x) -> qualifies_expedited_review(drug_x)) -> receives_priority_status(drug_x))",
        "natural": "Provided that it is not the case that the negation of drug X being approved for market leads to drug X qualifying for expedited review, then drug X receives priority status."
      },
      "(¬A3 → A4)": {
        "formal": "(¬A3 → A4)",
        "prover9": "(-A3 -> A4)",
        "prover9_expression": "(-has_funding(research_lab, project_alpha) -> receives_grant(research_lab, government_agency))",
        "natural": "If it is not the case that the research lab has funding for project alpha, then the research lab receives a grant from the government agency."
      },
      "(¬A3 → ¬A4)": {
        "formal": "(¬A3 → ¬A4)",
        "prover9": "(-A3 -> -A4)",
        "prover9_expression": "(-has_funding(research_lab, project_alpha) -> -receives_grant(research_lab, government_agency))",
        "natural": "In case it is not the case that the research lab has funding for project alpha, then it is not the case that the research lab receives a grant from the government agency."
      },
      "(¬G → A16)": {
        "formal": "(¬G → A16)",
        "prover9": "(-G -> A16)",
        "prover9_expression": "(-approved_for_market(drug_x) -> qualifies_expedited_review(drug_x))",
        "natural": "Whenever it is not the case that drug X is approved for market, then drug X qualifies for expedited review."
      },
      "A24": {
        "formal": "A24",
        "prover9": "A24",
        "prover9_expression": "has_collaboration(research_lab, company_a)",
        "natural": "The research lab has collaboration with company A."
      },
      "A26": {
        "formal": "A26",
        "prover9": "A26",
        "prover9_expression": "has_partnership(company_a, research_lab)",
        "natural": "Company A has a partnership with the research lab."
      },
      "A3": {
        "formal": "A3",
        "prover9": "A3",
        "prover9_expression": "has_funding(research_lab, project_alpha)",
        "natural": "The research lab has funding for project alpha."
      },
      "A40": {
        "formal": "A40",
        "prover9": "A40",
        "prover9_expression": "has_gmp_certification(facility_a)",
        "natural": "Facility A has GMP certification."
      },
      "A42": {
        "formal": "A42",
        "prover9": "A42",
        "prover9_expression": "provides_clinical_data(company_a)",
        "natural": "Company A provides clinical data."
      },
      "A43": {
        "formal": "A43",
        "prover9": "A43",
        "prover9_expression": "submits_dossier(company_a)",
        "natural": "Company A submits a dossier."
      },
      "A48": {
        "formal": "A48",
        "prover9": "A48",
        "prover9_expression": "responds_to_deficiency_letter(company_a)",
        "natural": "Company A responds to the deficiency letter."
      },
      "A49": {
        "formal": "A49",
        "prover9": "A49",
        "prover9_expression": "receives_deficiency_letter(company_a)",
        "natural": "Company A receives a deficiency letter."
      },
      "A6": {
        "formal": "A6",
        "prover9": "A6",
        "prover9_expression": "passes_safety_test(drug_x)",
        "natural": "Drug X passes the safety test."
      },
      "A7": {
        "formal": "A7",
        "prover9": "A7",
        "prover9_expression": "passes_efficacy_test(drug_x)",
        "natural": "Drug X passes the efficacy test."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "approved_for_market(drug_x)",
        "natural": "Drug X is approved for market."
      },
      "¬A14": {
        "formal": "¬A14",
        "prover9": "-A14",
        "prover9_expression": "-passes_toxicity_test(drug_x)",
        "natural": "It is not the case that drug X passes the toxicity test."
      },
      "¬A15": {
        "formal": "¬A15",
        "prover9": "-A15",
        "prover9_expression": "-fails_toxicity_test(drug_x)",
        "natural": "It is not the case that drug X fails the toxicity test."
      },
      "¬A16": {
        "formal": "¬A16",
        "prover9": "-A16",
        "prover9_expression": "-qualifies_expedited_review(drug_x)",
        "natural": "It is not the case that drug X qualifies for expedited review."
      },
      "¬A17": {
        "formal": "¬A17",
        "prover9": "-A17",
        "prover9_expression": "-receives_priority_status(drug_x)",
        "natural": "It is not the case that drug X receives priority status."
      },
      "¬A18": {
        "formal": "¬A18",
        "prover9": "-A18",
        "prover9_expression": "-delayed_approval(drug_x)",
        "natural": "It is not the case that approval of drug X is delayed."
      },
      "¬A21": {
        "formal": "¬A21",
        "prover9": "-A21",
        "prover9_expression": "-requests_extension(review_period)",
        "natural": "It is not the case that an extension of the review period is requested."
      },
      "¬A25": {
        "formal": "¬A25",
        "prover9": "-A25",
        "prover9_expression": "-secures_investment(company_a)",
        "natural": "It is not the case that company A secures investment."
      },
      "¬A27": {
        "formal": "¬A27",
        "prover9": "-A27",
        "prover9_expression": "-requires_retesting(drug_x)",
        "natural": "It is not the case that drug X requires retesting."
      },
      "¬A31": {
        "formal": "¬A31",
        "prover9": "-A31",
        "prover9_expression": "-fails_manufacturing_audit(drug_x)",
        "natural": "It is not the case that drug X fails the manufacturing audit."
      },
      "¬A39": {
        "formal": "¬A39",
        "prover9": "-A39",
        "prover9_expression": "-accepts_regulatory_submission(agency)",
        "natural": "It is not the case that the agency accepts the regulatory submission."
      },
      "¬A44": {
        "formal": "¬A44",
        "prover9": "-A44",
        "prover9_expression": "-provides_clinical_data(company_b)",
        "natural": "It is not the case that company B provides clinical data."
      },
      "¬A47": {
        "formal": "¬A47",
        "prover9": "-A47",
        "prover9_expression": "-requests_advisory_meeting(company_a)",
        "natural": "It is not the case that company A requests an advisory meeting."
      },
      "¬A50": {
        "formal": "¬A50",
        "prover9": "-A50",
        "prover9_expression": "-faces_regulatory_sanctions(company_a)",
        "natural": "It is not the case that company A faces regulatory sanctions."
      },
      "¬A8": {
        "formal": "¬A8",
        "prover9": "-A8",
        "prover9_expression": "-receives_fda_approval(drug_x)",
        "natural": "It is not the case that drug X receives FDA approval."
      }
    }
  }
}